An evaluation of the safety and efficacy of turoctocog alfa for hemophilia A

Boban, Ana; Hermans, Cédric

doi:10.1080/17474086.2020.1740586

Cited by 1 publication

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several clotting factor VIII concentrates are available for managing hemophilia A. Biotechnology is able to develop recombinant factor concentrates for replacement therapy [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Implanted subcutaneous versus intraperitoneal bioscaffold seeded with hepatocyte-like cells: functional evaluation

et al. 2021

View full text Add to dashboard Cite

Background and objectives The X-linked bleeding disorder, hemophilia A, is caused by defective production of factor VIII (FVIII). Hemophilic patients require regular FVIII infusions. Recombinant factor replacement poses the safest line of therapy. However, its main drawbacks are high expenses and the higher liability for formation of inhibitors. Recent studies confirmed the ability of bone marrow-derived stem cells to secrete FVIII. This study aims to generate bioscaffold from decellularized liver and subsequently seed it with trans-differentiated human stem cells into hepatic-like cells. This scaffold can then be implanted intraperitoneally or subcutaneously to provide FVIII. Methods After generation of the bioscaffold, seeding of discoid scaffolds with trans-differentiated human hepatocyte-like cells was performed. Then, the generated organoid was implanted into peritoneal cavity or subcutaneous tissue of experimental rats. Results Serum human FVIII was significantly increased in rats subjected to subcutaneous implantation compared intraperitoneal implantation. Immunostaining for detecting Cytokeratin 19 and human anti-globulin confirmed the presence of mature human hepatocytes that were significantly increased in subcutaneous implanted scaffold compared to the intraperitoneal one. Conclusion Implantation of decellularized bioscaffold seeded with trans-differentiated stem cells in rats was successful to establish production of FVIII. Subcutaneous implantation showed higher FVIII levels than intraperitoneal implantation.

show abstract

“…Several clotting factor VIII concentrates are available for managing hemophilia A. Biotechnology is able to develop recombinant factor concentrates for replacement therapy [ 3 ].…”

Section: Introductionmentioning

confidence: 99%